The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Of Pseudomonas, porins, pumps and carbapenems
Open accessAbstract
The carbapenems, imipenem and meropenem, are anomalous β-lactams in their antipseudomonal behaviour, as well as in their β-lactamase stability. In the case of imipenem, MICs for Pseudomonas aeruginosa isolates are unrelated to those of other β-lactams, whereas a strong relationship exists between the MICs of different penicillins and cephalosporins for most Pseudomonas isolates.1–4 This observation is partly because imipenem MICs are independent of derepression of the chromosomal AmpC β-lactamase, whereas this factor strongly co-determines the MICs of penicillins and cephalosporins.5 More critically, the MICs of imipenem are unaffected by the broad-spectrum intrinsic resistance expressed by many P. aeruginosa isolates, whereas this mechanism strongly co-determines the MICs of penicillins, cephalosporins and several unrelated drug classes, including quinolones, tetracyclines and chloramphenicol.1–4 Intrinsic resistance is expressed to a variable degree by all P. aeruginosa isolates, which are less susceptible than Enterobacteriaceae to most antibiotics. This behaviour was long thought to depend on impermeability,1,2 but is now found to involve an interplay of impermeability with multi-drug efflux, mediated principally by MexA-MexB-OprM.3,4,6,7 The MexB protein is a broad-spectrum pump, located in the cytoplasmic membrane; the OprM protein is a pore-forming protein that provides an exit portal through the outer membrane; and the MexA protein physically links these components. Upregulation of MexA-MexB-OprM arises at high frequency as a result of the nalB mutation at the mexR locus8–10 and raises the MICs of penicillins, cephalosporins, quinolones, tetracycline and chloramphenicol (Table), but not those of imipenem. nalB mutants may be selected in vitro, or during therapy with fluoroquinolones, penicillins and cephalosporins,11,12 and were the predominant phenotype selected when carbenicillin and ticarcillin were the mainstays of antipseudomonal treatment.13 The broad range of resistance conferred by upregulation is intriguing, and it is postulated that MexA-MexB-OprM has a natural role in removing amphipathic substances, which otherwise invade and disorganize the cytoplasmic membrane.14 Such a role would favour the evolution of a very broad substrate specificity. The lack of activity against imipenem may be because this carbapenem lacks any lipophilic phenyl or heterocyclic side chain(s). The advantage of evading intrinsic resistance is tempered by the fact that imipenem readily selects resistant mutants of P. aeruginosa, which are found to lack OprD protein (initially called D2 porin).15 The primary role of this protein is in the passive uptake of basic amino acids across the outer membrane, but it forms pores that are also permeable to carbapenems, though not to other β-lactams.16 Its loss raises the imipenem MICs from 1–2 mg/L, as for typical P. aeruginosa, to 8–32 mg/L, thus conferring clinical resistance. The MICs of non-carbapenems are unaffected. The resistance demands continued expression of the chromosomal AmpC β-lactamase, whether inducible or derepressed,17 but this aspect is peripheral in the present context. Carmeli et al.18 noted that selection of resistant P. aeruginosa during imipenem therapy was substantially more frequent than selection of ceftazidime-, piperacillinor ciprofloxacin-resistant mutants, and Calandra et al.19 found a 17% rate of resistance emerging during imipenem treatment of P. aeruginosa infections. The interactions of meropenem with these resistance mechanisms differ from those of imipenem, with implications that are provoking debate. The MICs of meropenem are 0.12–0.5 mg/L for typical strains of P. aeruginosa, and either upregulation of MexA-MexB-OprM or loss of OprD raises them to 2–4 mg/L,5,20 thereby reducing susceptibility without conferring resistance relative to either BSAC or NCCLS breakpoints. It is inferred that meropenem, like imipenem, can use the OprD pathway to enter the pseudomonal cell but that, unlike imipenem, it is recognized and ejected by MexB-mediated efflux, presumably because of its 2′ heterocyclic side chain. These differences between imipenem and meropenem allow arguments for either compound as ‘the less likely to cause resistance in P. aeruginosa’. The case for imipenem21 argues that, although it selects OprD– mutants, these have a narrow-spectrum insensitivity and remain fully susceptible to other drugs, whereas meropenem resistance co-depends on upregulation of MexA-MexB-OprM, a mechanism that compromises fluoroquinolones as well as other β-lactams. The case for meropenem17,22 is that substantive resistance is much harder to achieve than to imipenem, since two mutations (loss of OprD and upregulation of MexA-MexB-OprM) are needed rather than one. The likelihood that a cell will simultaneously undergo both mutations is c. <10–14, whereas imipenem-resistant mutants, lacking OprD, emerge at c. 10–7. Although formal analyses of the risk of meropenem
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa
Li, X. Z., Nikaido, H., & Poole, K. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.1948 · Cited by 643
Poole, K., Tetro, K., Zhao, Q., Neshat, S., Heinrichs, D. E., & Bianco, N. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.9.2021 · Cited by 324
Köhler, T., Epp, S. F., Curty, L. K., & Pechère, J.-C. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.20.6300-6305.1999 · Cited by 302
Livermore, D. M. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.9.2046 · Cited by 288
Self-citationLi, X. Z., Ma, D., Livermore, D. M., & Nikaido, H. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.8.1742 · Cited by 278
Self-citationZiha-Zarifi, I., Llanes, C., Köhler, T., Pechere, J.-C., & Plesiat, P. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.2.287 · Cited by 276
Emergence of Resistance to Imipenem During Therapy for Pseudomonas aeruginosa Infections
Quinn, J. P., Dudek, E. J., DiVincenzo, C. A., Lucks, D. A., & Lerner, S. A. (1986) · Journal of Infectious Diseases · doi:10.1093/infdis/154.2.289 · Cited by 276
Senda, K., Arakawa, Y., Nakashima, K., Ito, H., Ichiyama, S., Shimokata, K., Kato, N., & Ohta, M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.2.349 · Cited by 275
Köhler, T., Michea-Hamzehpour, M., Epp, S. F., & Pechere, J.-C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.2.424 · Cited by 268
Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa
Masuda, N., Sakagawa, E., & Ohya, S. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.645 · Cited by 226
Cited by
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
Huh, A. J., & Kwon, Y. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.002 · Cited by 1,864
Outer membrane permeability and antibiotic resistance
Delcour, A. H. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.11.005 · Cited by 1,762
Three Decades of β-Lactamase Inhibitors
Drawz, S. M., & Bonomo, R. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-09 · Cited by 1,709
Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?
Livermore, D. M. (2002) · Clinical Infectious Diseases · doi:10.1086/338782 · Cited by 1,453
Self-citationEfflux-mediated antimicrobial resistance
Poole, K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki171 · Cited by 1,082
Pseudomonas aeruginosa – a phenomenon of bacterial resistance
Strateva, T., & Yordanov, D. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.009142-0 · Cited by 803
How to manage Pseudomonas aeruginosa infections
Bassetti, M., Vena, A., Croxatto, A., Righi, E., & Guery, B. (2018) · Drugs in Context · doi:10.7573/dic.212527 · Cited by 746
Antibiotic resistance in Pseudomonas aeruginosa – Mechanisms, epidemiology and evolution
Botelho, J., Grosso, F., & Peixe, L. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.07.002 · Cited by 550
van der Zwaluw, K., de Haan, A., Pluister, G. N., Bootsma, H. J., de Neeling, A. J., & Schouls, L. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123690 · Cited by 486
Quale, J., Bratu, S., Gupta, J., & Landman, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1633-1641.2006 · Cited by 409
Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa
Rossolini, G. M., & Mantengoli, E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01161.x · Cited by 395
Liposomes as delivery systems for antibiotics
Drulis-Kawa, Z., & Dorotkiewicz-Jach, A. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.11.033 · Cited by 356
Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352
Karlowsky, J. A., Draghi, D. C., Jones, M. E., Thornsberry, C., Friedland, I. R., & Sahm, D. F. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1681-1688.2003 · Cited by 351
Taylor, P. K., Yeung, A. T. Y., & Hancock, R. E. W. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.09.003 · Cited by 340
Zavascki, A. P., Carvalhaes, C. G., Picão, R. C., & Gales, A. C. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.108 · Cited by 312
Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa
Rodríguez-Martínez, J.-M., Poirel, L., & Nordmann, P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00574-09 · Cited by 307
Mussi, M. A., Limansky, A. S., & Viale, A. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1432-1440.2005 · Cited by 276
Walther-Rasmussen, J., & Høiby, N. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm226 · Cited by 271
The Resistome of Pseudomonas aeruginosa in Relationship to Phenotypic Susceptibility
Kos, V. N., Déraspe, M., McLaughlin, R. E., Whiteaker, J. D., Roy, P. H., Alm, R. A., Corbeil, J., & Gardner, H. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03954-14 · Cited by 264
Metadata
- Authors
- Livermore, D. M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-03-01
- Volume
- 47
- Issue
- 3
- Pages
- 247-250
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W1963880769
- Cited by
- 391
- References
- 19
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.